{"data":{"id":"10.6084/m9.figshare.c.2128004.v1","type":"dois","attributes":{"doi":"10.6084/m9.figshare.c.2128004.v1","prefix":"10.6084","suffix":"m9.figshare.c.2128004.v1","identifiers":[],"alternateIdentifiers":[],"creators":[{"name":"Chen, Hsin-Hua","givenName":"Hsin-Hua","familyName":"Chen","affiliation":[],"nameIdentifiers":[]},{"name":"Chen, Yi-Ming","givenName":"Yi-Ming","familyName":"Chen","affiliation":[],"nameIdentifiers":[]},{"name":"Lai, Kuo-Lung","givenName":"Kuo-Lung","familyName":"Lai","affiliation":[],"nameIdentifiers":[]},{"name":"Lin, Ching-Heng","givenName":"Ching-Heng","familyName":"Lin","affiliation":[],"nameIdentifiers":[]},{"name":"Chen, Der-Yuan","givenName":"Der-Yuan","familyName":"Chen","affiliation":[],"nameIdentifiers":[]},{"name":"Tang, Chao-Hsiung","givenName":"Chao-Hsiung","familyName":"Tang","affiliation":[],"nameIdentifiers":[]}],"titles":[{"title":"Factors affecting discontinuation of adalimumab and etanercept therapy in anti-TNF-naïve patients with ankylosing spondylitis: Nationwide population-based cohort study"}],"publisher":"Taylor \u0026 Francis","container":{},"publicationYear":2015,"subjects":[{"subject":"Hematology"},{"subject":"Cancer"},{"subject":"Biological Sciences"},{"subject":"Immunology"},{"subject":"FOS: Clinical medicine","schemeUri":"http://www.oecd.org/science/inno/38235147.pdf","subjectScheme":"Fields of Science and Technology (FOS)"},{"subject":"Ecology"},{"subject":"FOS: Biological sciences","schemeUri":"http://www.oecd.org/science/inno/38235147.pdf","subjectScheme":"Fields of Science and Technology (FOS)"},{"subject":"Biotechnology"},{"subject":"Pharmacology"}],"contributors":[],"dates":[{"date":"2015-12-05","dateType":"Created"},{"date":"2019-08-19","dateType":"Updated"},{"date":"2015","dateType":"Issued"}],"language":null,"types":{"ris":"GEN","bibtex":"misc","citeproc":"article","schemaOrg":"Collection","resourceType":"Collection","resourceTypeGeneral":"Collection"},"relatedIdentifiers":[{"relationType":"IsIdenticalTo","relatedIdentifier":"10.6084/m9.figshare.c.2128004","relatedIdentifierType":"DOI"}],"relatedItems":[],"sizes":[],"formats":[],"version":null,"rightsList":[{"rights":"Creative Commons Attribution 4.0 International","rightsUri":"https://creativecommons.org/licenses/by/4.0/legalcode","schemeUri":"https://spdx.org/licenses/","rightsIdentifier":"cc-by-4.0","rightsIdentifierScheme":"SPDX"}],"descriptions":[{"description":"\u003ci\u003eObjectives.\u003c/i\u003e We investigated factors associated with discontinuation of anti-tumor necrosis factor (TNF) therapy in patients with ankylosing spondylitis (AS), who were anti-TNF-naïve and were given etanercept (ETN) or adalimumab (ADA).\u003ci\u003eMethods.\u003c/i\u003e This is a retrospective nationwide population-based cohort study. We identified 1401 anti-TNF-naïve patients with AS who initiated ETN (\u003ci\u003en\u003c/i\u003e = 441) or ADA (\u003ci\u003en\u003c/i\u003e = 960) and measured the duration of anti-TNF drug use. We recorded demographic and clinical data of all patients, and calculated adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) using Cox proportional hazard regression analyses.\u003ci\u003eResults\u003c/i\u003e. Overall, the ADA and ETN groups had similar risk for drug discontinuation (HR: 0.83; 95% CI: 0.63–1.08). In each group, concomitant use of methotrexate (MTX) or a non-steroidal anti-inflammatory drug was associated with a lower risk of discontinuation. Subgroup analysis indicated that concomitant MTX use reduced risk of discontinuation of ADA (HR: 0.54; 95% CI: 0.40–0.74), but not ETN (HR: 1.03; 95% CI: 0.65–1.63).\u003ci\u003eConclusions.\u003c/i\u003e This study of anti-TNF-naïve patients with AS indicated that users of ADA and ETN had similar overall risk of drug discontinuation. However, patients taking ADA with MTX had a lower risk of discontinuation than those taking ADA alone.","descriptionType":"Abstract"}],"geoLocations":[],"fundingReferences":[],"xml":"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","url":"https://tandf.figshare.com/collections/Factors_affecting_discontinuation_of_adalimumab_and_etanercept_therapy_in_anti_TNF_na_ve_patients_with_ankylosing_spondylitis_Nationwide_population_based_cohort_study/2128004/1","contentUrl":null,"metadataVersion":2,"schemaVersion":"http://datacite.org/schema/kernel-4","source":"mds","isActive":true,"state":"findable","reason":null,"viewCount":0,"viewsOverTime":[],"downloadCount":0,"downloadsOverTime":[],"referenceCount":0,"citationCount":0,"citationsOverTime":[],"partCount":0,"partOfCount":0,"versionCount":0,"versionOfCount":0,"created":"2015-12-05T21:23:09.000Z","registered":"2015-12-05T21:23:10.000Z","published":"2015","updated":"2024-03-21T09:32:47.000Z"},"relationships":{"client":{"data":{"id":"figshare.ars","type":"clients"}},"provider":{"data":{"id":"otjm","type":"providers"}},"media":{"data":{"id":"10.6084/m9.figshare.c.2128004.v1","type":"media"}},"references":{"data":[]},"citations":{"data":[]},"parts":{"data":[]},"partOf":{"data":[]},"versions":{"data":[]},"versionOf":{"data":[]}}}}